USA - NASDAQ:ARAY - US0043971052 - Common Stock
The current stock price of ARAY is 1.12 USD. In the past month the price decreased by -34.81%. In the past year, price decreased by -30.59%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.85 | 224.50B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.28 | 204.56B | ||
| BSX | BOSTON SCIENTIFIC CORP | 35.61 | 155.64B | ||
| SYK | STRYKER CORP | 28.39 | 142.95B | ||
| IDXX | IDEXX LABORATORIES INC | 56.25 | 56.74B | ||
| BDX | BECTON DICKINSON AND CO | 13.55 | 56.00B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.77 | 50.96B | ||
| RMD | RESMED INC | 25.66 | 37.07B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.41 | 34.39B | ||
| PODD | INSULET CORP | 73.52 | 23.65B | ||
| DXCM | DEXCOM INC | 32.29 | 23.55B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.17 | 17.90B |
Accuray, Inc. is a radiation therapy company, which engages in manufacturing medical equipment. The company is headquartered in Madison, Wisconsin and currently employs 990 full-time employees. The company went IPO on 2007-02-08. The firm develops, manufactures, sells and supports solutions that are designed to deliver radiation treatments for complex cases. Its solutions are designed to advance patient care: during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, it also provides services, which include post-contract customer support (warranty period services and post-warranty services), installation services, training, and other professional services.
ACCURAY INC
1240 Deming Way
Madison WISCONSIN 94089 US
CEO: Joshua H. Levine
Employees: 990
Phone: 16088242800
Accuray, Inc. is a radiation therapy company, which engages in manufacturing medical equipment. The company is headquartered in Madison, Wisconsin and currently employs 990 full-time employees. The company went IPO on 2007-02-08. The firm develops, manufactures, sells and supports solutions that are designed to deliver radiation treatments for complex cases. Its solutions are designed to advance patient care: during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, it also provides services, which include post-contract customer support (warranty period services and post-warranty services), installation services, training, and other professional services.
The current stock price of ARAY is 1.12 USD. The price decreased by -5.08% in the last trading session.
ARAY does not pay a dividend.
ARAY has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
ACCURAY INC (ARAY) currently has 990 employees.
ACCURAY INC (ARAY) has a market capitalization of 126.25M USD. This makes ARAY a Micro Cap stock.
ACCURAY INC (ARAY) will report earnings on 2026-02-03.
ChartMill assigns a fundamental rating of 3 / 10 to ARAY. ARAY has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months ARAY reported a non-GAAP Earnings per Share(EPS) of -0.13. The EPS increased by 24.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.23% | ||
| ROE | -31.22% | ||
| Debt/Equity | 2.06 |
9 analysts have analysed ARAY and the average price target is 4.85 USD. This implies a price increase of 332.59% is expected in the next year compared to the current price of 1.12.
For the next year, analysts expect an EPS growth of -23.1% and a revenue growth 4.49% for ARAY